FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1502524639> ?p ?o ?g. }

• W1502524639 endingPage "2016" @default.
• W1502524639 startingPage "2005" @default.
• W1502524639 abstract "Individuals with diabetes are at increased risk of cardiovascular morbidity and mortality, although typically their plasma concentrations of LDL cholesterol are similar to those in the general population. Previous evidence about the effects of lowering cholesterol in people with diabetes has been limited, and most diabetic patients do not currently receive cholesterol-lowering therapy despite their increased risk.5963 UK adults (aged 40-80 years) known to have diabetes, and an additional 14573 with occlusive arterial disease (but no diagnosed diabetes), were randomly allocated to receive 40 mg simvastatin daily or matching placebo. Prespecified analyses in these prior disease subcategories, and other relevant subcategories, were of first major coronary event (ie, non-fatal myocardial infarction or coronary death) and of first major vascular event (ie, major coronary event, stroke or revascularisation). Analyses were also conducted of subsequent vascular events during the scheduled treatment period. Comparisons are of all simvastatin-allocated versus all placebo-allocated participants (ie, intention to treat), which yielded an average difference in LDL cholesterol of 1.0 mmol/L (39 mg/dL) during the 5-year treatment period.Both among the participants who presented with diabetes and among those who did not, there were highly significant reductions of about a quarter in the first event rate for major coronary events, for strokes, and for revascularisations. For the first occurrence of any of these major vascular events among participants with diabetes, there was a definite 22% (95% CI 13-30) reduction in the event rate (601 [20.2%] simvastatin-allocated vs 748 [25.1%] placebo-allocated, p<0.0001), which was similar to that among the other high-risk individuals studied. There were also highly significant reductions of 33% (95% CI 17-46, p=0.0003) among the 2912 diabetic participants who did not have any diagnosed occlusive arterial disease at entry, and of 27% (95% CI 13-40, p=0.0007) among the 2426 diabetic participants whose pretreatment LDL cholesterol concentration was below 3.0 mmol/L (116 mg/dL). The proportional reduction in risk was also about a quarter among various other subcategories of diabetic patient studied, including: those with different duration, type, or control of diabetes; those aged over 65 years at entry or with hypertension; and those with total cholesterol below 5.0 mmol/L (193 mg/dL). In addition, among participants who had a first major vascular event following randomisation, allocation to simvastatin reduced the rate of subsequent events during the scheduled treatment period.The present study provides direct evidence that cholesterol-lowering therapy is beneficial for people with diabetes even if they do not already have manifest coronary disease or high cholesterol concentrations. Allocation to 40 mg simvastatin daily reduced the rate of first major vascular events by about a quarter in a wide range of diabetic patients studied. After making allowance for non-compliance, actual use of this statin regimen would probably reduce these rates by about a third. For example, among the type of diabetic patient studied without occlusive arterial disease, 5 years of treatment would be expected to prevent about 45 people per 1000 from having at least one major vascular event (and, among these 45 people, to prevent about 70 first or subsequent events during this treatment period). Statin therapy should now be considered routinely for all diabetic patients at sufficiently high risk of major vascular events, irrespective of their initial cholesterol concentrations." @default.
• W1502524639 created "2016-06-24" @default.
• W1502524639 creator A5025156367 @default.
• W1502524639 creator A5041941850 @default.
• W1502524639 creator A5046786726 @default.
• W1502524639 creator A5072077709 @default.
• W1502524639 creator A5090621185 @default.
• W1502524639 date "2003-06-01" @default.
• W1502524639 modified "2023-10-11" @default.
• W1502524639 title "MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial" @default.
• W1502524639 cites W105962391 @default.
• W1502524639 cites W137344628 @default.
• W1502524639 cites W1500963439 @default.
• W1502524639 cites W180946569 @default.
• W1502524639 cites W1985628753 @default.
• W1502524639 cites W2000366267 @default.
• W1502524639 cites W2013256551 @default.
• W1502524639 cites W2014759828 @default.
• W1502524639 cites W2018715171 @default.
• W1502524639 cites W2028693103 @default.
• W1502524639 cites W2031185570 @default.
• W1502524639 cites W2031484324 @default.
• W1502524639 cites W2038252730 @default.
• W1502524639 cites W2053365438 @default.
• W1502524639 cites W2055864845 @default.
• W1502524639 cites W2061489988 @default.
• W1502524639 cites W2072514425 @default.
• W1502524639 cites W2081960656 @default.
• W1502524639 cites W2082768646 @default.
• W1502524639 cites W2094910754 @default.
• W1502524639 cites W2100500261 @default.
• W1502524639 cites W2115728877 @default.
• W1502524639 cites W2128300830 @default.
• W1502524639 cites W2129750583 @default.
• W1502524639 cites W2147018838 @default.
• W1502524639 cites W2155598961 @default.
• W1502524639 cites W2161261413 @default.
• W1502524639 cites W2162642883 @default.
• W1502524639 cites W2214291492 @default.
• W1502524639 cites W2297753288 @default.
• W1502524639 cites W2322095705 @default.
• W1502524639 cites W2331274940 @default.
• W1502524639 cites W2337454357 @default.
• W1502524639 cites W2478782318 @default.
• W1502524639 cites W3198570063 @default.
• W1502524639 cites W38523360 @default.
• W1502524639 cites W4237787323 @default.
• W1502524639 cites W4238183455 @default.
• W1502524639 cites W4238251256 @default.
• W1502524639 cites W424467158 @default.
• W1502524639 doi "https://doi.org/10.1016/s0140-6736(03)13636-7" @default.
• W1502524639 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/12814710" @default.
• W1502524639 hasPublicationYear "2003" @default.
• W1502524639 type Work @default.
• W1502524639 sameAs 1502524639 @default.
• W1502524639 citedByCount "2411" @default.
• W1502524639 countsByYear W15025246392012 @default.
• W1502524639 countsByYear W15025246392013 @default.
• W1502524639 countsByYear W15025246392014 @default.
• W1502524639 countsByYear W15025246392015 @default.
• W1502524639 countsByYear W15025246392016 @default.
• W1502524639 countsByYear W15025246392017 @default.
• W1502524639 countsByYear W15025246392018 @default.
• W1502524639 countsByYear W15025246392019 @default.
• W1502524639 countsByYear W15025246392020 @default.
• W1502524639 countsByYear W15025246392021 @default.
• W1502524639 countsByYear W15025246392022 @default.
• W1502524639 countsByYear W15025246392023 @default.
• W1502524639 crossrefType "journal-article" @default.
• W1502524639 hasAuthorship W1502524639A5025156367 @default.
• W1502524639 hasAuthorship W1502524639A5041941850 @default.
• W1502524639 hasAuthorship W1502524639A5046786726 @default.
• W1502524639 hasAuthorship W1502524639A5072077709 @default.
• W1502524639 hasAuthorship W1502524639A5090621185 @default.
• W1502524639 hasConcept C126322002 @default.
• W1502524639 hasConcept C127413603 @default.
• W1502524639 hasConcept C134018914 @default.
• W1502524639 hasConcept C142724271 @default.
• W1502524639 hasConcept C164705383 @default.
• W1502524639 hasConcept C204787440 @default.
• W1502524639 hasConcept C27081682 @default.
• W1502524639 hasConcept C2776329913 @default.
• W1502524639 hasConcept C2776839432 @default.
• W1502524639 hasConcept C2780645631 @default.
• W1502524639 hasConcept C2908647359 @default.
• W1502524639 hasConcept C500558357 @default.
• W1502524639 hasConcept C555293320 @default.
• W1502524639 hasConcept C71924100 @default.
• W1502524639 hasConcept C78519656 @default.
• W1502524639 hasConcept C99454951 @default.
• W1502524639 hasConceptScore W1502524639C126322002 @default.
• W1502524639 hasConceptScore W1502524639C127413603 @default.
• W1502524639 hasConceptScore W1502524639C134018914 @default.
• W1502524639 hasConceptScore W1502524639C142724271 @default.
• W1502524639 hasConceptScore W1502524639C164705383 @default.
• W1502524639 hasConceptScore W1502524639C204787440 @default.
• W1502524639 hasConceptScore W1502524639C27081682 @default.
• W1502524639 hasConceptScore W1502524639C2776329913 @default.

• next